Immuno Oncology Assays Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

Immuno-oncology assays are laboratory-based diagnostic tools used to identify and quantify biomarkers that influence the immune system's response to cancer. These tests are critical for patient stratification, drug development, and treatment monitoring in the rapidly expanding field of cancer immunotherapy. The global market was valued at approximately $6.06 billion in 2025 and is forecast to grow at a CAGR of around 11.74% over the coming years, positioning it among the faster-growing segments within the broader in-vitro diagnostics industry.

• •Market size in 2025 estimated between roughly $5.5 billion and $6.9 billion across multiple commercial research sources, with a consensus near $6.3 billion
• •Projected to reach approximately $15-21 billion by 2032-2035, representing a near-doubling to tripling of market value over the forecast period
• •Applications span companion diagnostics, clinical trial patient enrollment, therapeutic drug monitoring, and drug development support

The increasing global burden of cancer is a foundational driver, with the World Health Organization estimating nearly 20 million new cancer cases globally each year, creating sustained demand for diagnostic tools that enable targeted treatment. The proliferation of immune checkpoint inhibitors, CAR-T therapies, and other immunotherapies has made biomarker testing essential for identifying which patients are most likely to benefit. Furthermore, the paradigm shift toward precision medicine and personalized oncology has elevated the importance of companion diagnostics, which require sophisticated immuno-oncology assays to function effectively.

• •Rising cancer prevalence worldwide, particularly lung, breast, colorectal, and melanoma cancers that are commonly treated with immunotherapies
• •Expanding pipeline of immuno-oncology drugs in clinical development and regulatory approval requiring companion diagnostic assays
• •Growing adoption of biomarker-driven treatment protocols and regulatory initiatives supporting personalized medicine approaches

The immuno-oncology assays market is segmented by assay type, including flow cytometry, ELISA, immunofluorescence, PCR-based assays, and next-generation sequencing-based tests, each serving distinct clinical and research purposes. Geographically, North America holds the largest market share, driven by high healthcare spending, advanced research infrastructure, and early adoption of novel cancer therapies. The Asia-Pacific region is expected to exhibit the fastest growth, fueled by rising cancer incidence, improving healthcare access, and growing investment in pharmaceutical research and development.

• •North America dominates the market, accounting for roughly 40-45% of global share, supported by FDA companion diagnostic regulations and a mature biopharmaceutical sector
• •Europe represents the second-largest regional market, with strong contributions from Germany, the UK, and France driven by centralized regulatory pathways and oncology research activity
• •Asia-Pacific is the fastest-growing region, with China, Japan, and India emerging as key markets due to increasing cancer burden, healthcare infrastructure investment, and local manufacturing capabilities

What are the recent trends and outlook?

A significant trend shaping the immuno-oncology assays market is the shift toward multiplex assays and next-generation biomarker panels, which enable simultaneous detection of multiple immune markers to provide a more comprehensive picture of the tumor microenvironment. Liquid biopsy technology is gaining prominence as a non-invasive alternative to tissue-based assays, particularly for monitoring treatment response and detecting resistance mechanisms. Additionally, the integration of artificial intelligence and machine learning in image analysis for immuno-oncology assays is improving the reproducibility and accuracy of biomarker quantification, while regulatory agencies continue to refine frameworks for companion diagnostic approval.

• •Multiplex immuno-oncology assays capable of profiling multiple immune markers simultaneously are gaining clinical and commercial traction
• •Liquid biopsy-based assays for circulating tumor DNA and immune cell profiling are emerging as tools for non-invasive monitoring of immunotherapy response
• •Regulatory harmonization efforts, including FDA guidance on companion diagnostic co-development, are shaping how assays are validated and brought to market alongside novel therapies